CIC
NKTR icon

Cornercap Investment Counsel’s Nektar Therapeutics NKTR Stock Holding History

Cornercap Investment Counsel’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,442
Closed -$46.8K – 634
2023
Q1 		$46.8K Buy
4,442
+149
+3% +$4.51K 0.01% 543
2022
Q4 		$146K Hold
4,293
– – 0.03% 525
2022
Q3 		$206K Buy
4,293
+1,361
+46% +$81K 0.04% 492
2022
Q2 		$167K Buy
+2,932
New +$185K 0.03% 495

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Cornercap Investment Counsel's NKTR Position: Q2 2023 in Review

Cornercap Investment Counsel sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 4,442 shares — an estimated $46.8K sold.

Cornercap Investment Counsel first reported a position in NKTR in Q2 2022 and held it in 4 quarters. The position peaked at $206K in Q3 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Cornercap Investment Counsel reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 4,442 Nektar Therapeutics shares in Q2 2023, an estimated $46.8K.
  • Cornercap Investment Counsel first reported a position in Nektar Therapeutics in Q2 2022 and held it in 4 quarters.
  • Cornercap Investment Counsel's Nektar Therapeutics position peaked at $206K in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Cornercap Investment Counsel's 13F filing for Q2 2023, filed 11 Aug 2023.